Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Sangamo Therapeutics, Inc. operates as a biotechnology company. The Company focuses on research and development of genomic therapies, as well as develops medicines for patient with genetic diseases. Sangamo Therapeutics serves customers in the United States.
Website: sangamo.com



Growth: Bad revenue growth rate -3.6%, there is slowdown compared to average historical growth rates 23.2%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -160.0%. On average the margin is decreasing steadily. Gross margin is high, +100.0%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 100% of quarters (showing a gain of +$0.11 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 206.4% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 86.0% higher than minimum and 95.5% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -5.5x by EV / Sales multiple

Key Financials (Download financials)

Ticker: SGMO
Share price, USD:  (+5.9%)0.5526
year average price 0.8130  


year start price 1.3400 2023-05-05

max close price 1.5100 2023-05-23

min close price 0.2971 2023-11-10

current price 0.5526 2024-05-03
Common stocks: 154 345 000

Dividend Yield:  0.0%
Last revenue growth (y/y):  -3.6%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  23.2%
Historical growth of EBITDA:  -16.7%
EV / Sales: -2.0x
Margin (EBITDA LTM / Revenue): -160.0%
Fundamental value created in LTM:
Market Cap ($m): 85
Net Debt ($m): -307
EV (Enterprise Value): -222
Price to Book: 1.0x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-03-12Business Wire

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast

2023-10-26Zacks Investment Research

Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

2023-10-24Business Wire

Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)

2023-08-08Zacks Investment Research

Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol SGMO SGMO SGMO SGMO SGMO SGMO
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-03-13 2023-11-01 2023-08-08 2023-05-08 2023-02-23 2022-11-03
acceptedDate 2024-03-13 07:47:35 2023-11-01 16:17:10 2023-08-08 16:15:13 2023-05-08 17:11:08 2023-02-22 21:45:41 2022-11-03 16:02:33
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
revenue 2M 9M 7M 158M 27M 26M
costOfRevenue 3M 10M 4M 0 0 0
grossProfit -940 001 -113 000 3M 158M 27M 26M
grossProfitRatio -0.460 -0.012 0.377 1.000 1.000 1.000
researchAndDevelopmentExpenses 51M 57M 63M 63M 66M 65M
generalAndAdministrativeExpenses 13M 14M 16M 18M 16M 16M
sellingAndMarketingExpenses -3M 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 10M 14M 16M 18M 16M 16M
otherExpenses 0 45M 51M 59M 0 0
operatingExpenses 61M 71M 79M 81M 83M 81M
costAndExpenses 64M 71M 79M 81M 83M 81M
interestIncome 1M 4M 3M 0 -2M 2M
interestExpense 0 0 0 114M -4M 2M
depreciationAndAmortization 3M 90M 6M 6M 5M 0
ebitda -59M -17M -15M 141M -55M -55M
ebitdaratio -29.080 -1.789 -2.150 0.891 -2.034 -2.075
operatingIncome -62M -106M -124M 135M -55M -55M
operatingIncomeRatio -30.540 -11.322 -18.079 0.856 -2.034 -2.075
totalOtherIncomeExpensesNet 2M -45M -51M -114M 4M 2M
incomeBeforeTax -61M -103M -121M 21M -52M -53M
incomeBeforeTaxRatio -29.661 -10.948 -17.669 0.135 -1.899 -2.008
incomeTaxExpense -272 000 1M -6M 194 000 259 000 30 000
netIncome -60M -104M -115M 21M -52M -53M
netIncomeRatio -29.528 -11.084 -16.753 0.134 -1.909 -2.009
eps -0.340 -0.590 -0.660 0.130 -0.320 -0.340
epsdiluted -0.340 -0.590 -0.660 0.120 -0.320 -0.340
weightedAverageShsOut 178M 177M 174M 169M 165M 158M
weightedAverageShsOutDil 178M 177M 174M 169M 165M 158M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol SGMO SGMO SGMO SGMO SGMO SGMO
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-03-13 2023-11-01 2023-08-08 2023-05-08 2023-02-23 2022-11-03
acceptedDate 2024-03-13 07:47:35 2023-11-01 16:17:10 2023-08-08 16:15:13 2023-05-08 17:11:08 2023-02-22 21:45:41 2022-11-03 16:02:33
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 45M 57M 67M 78M 100M 95M
shortTermInvestments 36M 76M 76M 127M 177M 219M
cashAndShortTermInvestments 81M 132M 143M 205M 278M 350M
netReceivables 1M 2M 4M 8M 4M 5M
inventory 0 2.000 0 0 0 0
otherCurrentAssets 12M 14M 13M 14M 18M 18M
totalCurrentAssets 94M 148M 160M 227M 300M 337M
propertyPlantEquipmentNet 53M 56M 107M 109M 126M 121M
goodwill 0 0 0 0 38M 35M
intangibleAssets 0 0 0 52M 51M 46M
goodwillAndIntangibleAssets 0 0 0 52M 88M 81M
longTermInvestments 2M 2M 39M 36M 30M 37M
taxAssets 0 0 0 6M 0 0
otherNonCurrentAssets 17M 15M 19M 11M 19M 19M
totalNonCurrentAssets 71M 72M 165M 213M 262M 257M
otherAssets 1.000 0 0 0 0 0
totalAssets 165M 220M 325M 441M 563M 594M
accountPayables 15M 15M 15M 20M 22M 17M
shortTermDebt 5M 0 0 0 4M 0
taxPayables 0 0 0 0 0 0
deferredRevenue 0 1M 7M 10M 52M 72M
otherCurrentLiabilities 28M 32M 32M 28M 33M 33M
totalCurrentLiabilities 48M 48M 54M 58M 112M 122M
longTermDebt 34M 35M 36M 38M 39M 40M
deferredRevenueNonCurrent 0 0 0 2M 109M 116M
deferredTaxLiabilitiesNonCurrent 0 0 0 6M 6M 6M
otherNonCurrentLiabilities 1M 1M 1M 1M 1M 73M
totalNonCurrentLiabilities 35M 36M 38M 47M 156M 162M
otherLiabilities 0 0 0 0 0 0
capitalLeaseObligations 34M 35M 36M 38M 43M 40M
totalLiabilities 82M 85M 91M 105M 268M 285M
preferredStock 0 0 0 0 0 0
commonStock 2M 2M 2M 2M 2M 2M
retainedEarnings -1 406M -1 346M -1 242M -1 127M -1 149M -1 097M
accumulatedOtherComprehensiveIncomeLoss -5M -7M -6M -6M -8M -19M
othertotalStockholdersEquity 1 492M 1 486M 1 480M 1 467M 1 450M 1 423M
totalStockholdersEquity 83M 135M 234M 336M 295M 309M
totalEquity 83M 135M 234M 336M 295M 309M
totalLiabilitiesAndStockholdersEquity 165M 220M 325M 441M 563M 594M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 165M 220M 325M 441M 563M 594M
totalInvestments 37M 76M 76M 163M 207M 256M
totalDebt 38M 35M 36M 38M 43M 40M
netDebt -7M -22M -30M -41M -57M -55M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol SGMO SGMO SGMO SGMO SGMO SGMO
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-03-13 2023-11-01 2023-08-08 2023-05-08 2023-02-23 2022-11-03
acceptedDate 2024-03-13 07:47:35 2023-11-01 16:17:10 2023-08-08 16:15:13 2023-05-08 17:11:08 2023-02-22 21:45:41 2022-11-03 16:02:33
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
netIncome -60M -104M -115M 21M -52M -53M
depreciationAndAmortization 3M 7M 6M 6M 5M 5M
deferredIncomeTax -140 000 182 000 51M 0 0 0
stockBasedCompensation 6M 6M 7M 8M 8M 8M
changeInWorkingCapital 783 000 -3M -3M -159M -18M -13M
accountsReceivables 425 000 2M 4M -3M 844 000 1M
inventory 0 2M 1M 0 0 0
accountsPayables 11M -2M -1M -2M 13M 0
otherWorkingCapital -10M -4M -8M -154M -32M -14M
otherNonCashItems 26 000 46M -7M 58M -918 000 -531 000
netCashProvidedByOperatingActivities -51M -47M -61M -66M -57M -54M
investmentsInPropertyPlantAndEquipment -3M -3M -6M -10M -7M -4M
acquisitionsNet 0 -40M -48M 0 0 0
purchasesOfInvestments 0 -7M -16M -36M -52M -96M
salesMaturitiesOfInvestments 40M 48M 64M 82M 102M 87M
otherInvestingActivites 0 40M 48M 0 0 0
netCashUsedForInvestingActivites 38M 38M 42M 36M 43M -13M
debtRepayment 0 0 0 0 0 0
commonStockIssued 216 000 720 000 6M 9M 19M 44M
commonStockRepurchased 0 -101 000 719 000 0 2M 0
dividendsPaid 0 0 0 0 0 0
otherFinancingActivites -49 000 -719 000 -194 000 -1M -1M -101 000
netCashUsedProvidedByFinancingActivities 167 000 -100 000 7M 8M 20M 44M
effectOfForexChangesOnCash 1M -550 000 313 000 367 000 775 000 127 000
netChangeInCash -11M -10M -11M -22M 6M -23M
cashAtEndOfPeriod 45M 58M 68M 80M 102M 96M
cashAtBeginningOfPeriod 57M 68M 80M 102M 96M 119M
operatingCashFlow -51M -47M -61M -66M -57M -54M
capitalExpenditure -3M -3M -6M -10M -7M -4M
freeCashFlow -53M -50M -66M -77M -65M -58M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

2023 q3
2023-11-02 ET (fiscal 2023 q3)
2023 q2
2023-08-08 ET (fiscal 2023 q2)
2023 q1
2023-04-27 ET (fiscal 2023 q1)
2022 q4
2023-02-22 ET (fiscal 2022 q4)
2022 q3
2022-11-03 ET (fiscal 2022 q3)
2022 q2
2022-08-04 ET (fiscal 2022 q2)
2022 q1
2022-05-05 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-05-02 20:15 ET
Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast
2024-04-22 20:35 ET
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
2024-03-22 12:05 ET
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
2024-03-13 12:05 ET
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
2024-03-13 12:01 ET
Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs
2024-03-12 22:30 ET
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast
2024-02-12 13:05 ET
Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease
2024-02-05 23:01 ET
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile
2023-11-01 20:01 ET
Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results
2023-10-25 20:15 ET
Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast
2023-10-24 06:01 ET
Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
2023-09-20 20:15 ET
Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit
2023-08-08 20:01 ET
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results
2023-08-01 20:15 ET
Sangamo Therapeutics Announces Second Quarter 2023 Conference Call and Webcast
2023-07-20 12:05 ET
Sangamo Therapeutics and Chroma Medicine Announce Option and License Agreement to Evaluate and Develop Zinc Finger Proteins for Epigenetic Editing
2023-07-17 12:05 ET
Sangamo Therapeutics Announces Research Evaluation and Option Agreement With Prevail, a Wholly Owned Subsidiary of Lilly, for Novel Engineered Capsids
2023-06-29 12:05 ET
Sangamo Therapeutics and Voyager Therapeutics Enter License Agreement for Epigenetic Regulation Treatment of Prion Disease
2023-05-22 12:05 ET
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for Isaralgagene Civaparvovec for the Treatment of Fabry Disease
2023-05-16 12:00 ET
Sangamo Therapeutics Announces Appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer
2023-05-02 20:30 ET
Sangamo Therapeutics to Present Pre-clinical Data From Its Genomic Engineering Platform at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
2023-04-26 21:28 ET
Sangamo Therapeutics Announces Strategic Update and Reports Preliminary First Quarter 2023 Financial Results
2023-04-19 20:15 ET
Sangamo Therapeutics Announces First Quarter 2023 Conference Call and Webcast
2023-02-22 21:01 ET
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results
2023-02-22 20:01 ET
Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease
2023-02-21 14:01 ET
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2022 Conference Call and Webcast
2022-11-03 20:01 ET
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results
2022-10-27 20:15 ET
Sangamo Therapeutics Announces Third Quarter 2022 Conference Call and Webcast
2022-10-12 07:01 ET
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Nine Patients
2022-08-30 10:00 ET
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Clinical Study Showing Continued Tolerability and Sustained Elevated α-gal A Enzyme Activity in Five Longest Treated Patients
2022-08-04 20:01 ET
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results
2022-07-28 20:15 ET
Sangamo Therapeutics Announces Second Quarter 2022 Conference Call and Webcast
2022-07-21 12:05 ET
European Orphan Medicinal Product Designation Granted to Sangamo Therapeutics Investigational CAR-Treg Cell Therapy TX200 for Solid Organ Transplantation
2022-06-01 20:30 ET
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
2022-05-05 20:01 ET
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results
2022-05-02 20:30 ET
Sangamo Therapeutics to Present Data From Its Next-Generation Technologies at 2022 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
2022-04-28 20:15 ET
Sangamo Therapeutics Announces First Quarter 2022 Conference Call and Webcast
2022-04-21 20:30 ET
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
2022-03-29 12:05 ET
Sangamo Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of Investigational CAR-Treg Cell Therapy TX200 in Kidney Transplantation
2022-02-28 22:00 ET
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
2022-02-24 21:01 ET
Sangamo Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
2022-02-17 21:30 ET
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2021 Conference Call and Webcast
2022-02-07 23:00 ET
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Patients With Fabry Disease
2022-01-06 13:00 ET
Sangamo Announces Transition of SAR445136 Sickle Cell Disease Program From Sanofi to Sangamo
2022-01-04 22:00 ET
Sangamo Therapeutics Announces Participation at H.C. Wainwright BIOCONNECT Virtual Conference
2021-12-12 21:30 ET
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy
2021-12-12 14:00 ET
Sangamo Therapeutics Announces Updated Preliminary SAR445136 Phase 1/2 Proof-of-Concept Data Showing Tolerability and Sustained Effects in Sickle Cell Disease
2021-11-09 13:30 ET
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
2021-11-04 13:05 ET
Sangamo Therapeutics Reports Recent Business and Clinical Highlights and Third Quarter 2021 Financial Results
2021-11-04 12:00 ET
Sangamo Therapeutics Announces Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Patients With Fabry Disease
2021-10-28 20:30 ET
Sangamo Therapeutics Announces Third Quarter 2021 Conference Call and Webcast
2021-08-31 12:30 ET
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
2021-08-09 20:30 ET
Sangamo Therapeutics Announces Participation at 2021 Wedbush PacGrow Healthcare Conference
2021-08-05 20:01 ET
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results
2021-07-29 20:30 ET
Sangamo Therapeutics Announces Second Quarter 2021 Conference Call and Webcast
2021-05-24 20:15 ET
Sangamo Therapeutics Appoints Prathyusha Duraibabu, CPA, MBA, to Chief Financial Officer
2021-05-21 12:30 ET
Sangamo Therapeutics Announces Participation at Jefferies Healthcare Conference
2021-05-04 20:01 ET
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results
2021-05-03 20:30 ET
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
2021-04-27 20:30 ET
Sangamo Therapeutics Announces Presentations at 2021 Annual Meeting of the American Society of Gene & Cell Therapy
2021-04-27 20:15 ET
Sangamo Therapeutics Announces First Quarter 2021 Conference Call and Webcast
2021-03-25 12:30 ET
Sangamo Therapeutics Announces Participation at Guggenheim Healthcare Talks: 2021 Genomic Medicines & Rare Disease
2021-03-17 20:30 ET
Sangamo Announces EMA Releases Details Supporting Orphan Designation for BIVV003 for the Treatment of Sickle Cell Disease
2021-02-24 21:01 ET
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results
2021-02-18 21:15 ET
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
2021-02-17 21:15 ET
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2020 Conference Call and Webcast
2021-02-01 21:05 ET
Sangamo Therapeutics Appoints Rob Schott, MD, MPH, FACC, as Head of Development; Elevates Jason Fontenot, PhD to Chief Scientific Officer
2021-01-06 21:10 ET
Sangamo Therapeutics Announces Departure of Chief Financial Officer Sung Lee
2021-01-05 13:00 ET
Sangamo Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
2020-12-07 12:00 ET
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels in 3x10¹³ VG/KG Cohort Through One Year Following Hemophilia A Gene Therapy
2020-11-05 13:00 ET
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
2020-11-04 21:01 ET
Sangamo Therapeutics Reports Business Highlights and Third Quarter 2020 Financial Results
2020-10-28 20:15 ET
Sangamo Therapeutics Announces Third Quarter 2020 Conference Call and Webcast
2020-10-07 10:45 ET
Pfizer and Sangamo Dose First Participant in Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatment
2020-09-28 12:30 ET
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
2020-09-11 12:30 ET
Sangamo Therapeutics Appoints Kenneth Hillan to Its Board of Directors
2020-09-02 20:15 ET
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
2020-08-10 12:30 ET
Sangamo Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Conference
2020-08-05 20:01 ET
Sangamo Therapeutics Reports Business Highlights and Second Quarter 2020 Financial Results
2020-07-30 11:00 ET
Sangamo Announces Global Collaboration With Novartis to Develop Genomic Medicines for Autism and Other Neurodevelopmental Disorders
2020-07-29 20:15 ET
Sangamo Therapeutics Announces Second Quarter 2020 Conference Call and Webcast
2020-06-24 12:00 ET
Sangamo Announces R&D Organization Changes
2020-05-29 13:00 ET
Sangamo Therapeutics Announces Participation at the Jefferies Virtual Healthcare Conference
2020-05-12 13:15 ET
Sangamo Therapeutics Announces Participation at the Bank of America 2020 Health Care Conference
2020-05-11 20:01 ET
Sangamo Therapeutics Reports Business Highlights and First Quarter 2020 Financial Results
2020-05-07 21:15 ET
Sangamo Therapeutics Announces Virtual Format for 2020 Annual Meeting
2020-05-04 20:15 ET
Sangamo Therapeutics Announces First Quarter 2020 Conference Call and Webcast
2020-04-28 20:30 ET
Sangamo Therapeutics Announces Presentations at 2020 Annual Meeting of the American Society of Gene & Cell Therapy
2020-04-21 11:00 ET
Mogrify and Sangamo announce collaboration and exclusive license agreement for Mogrify’s iPSC- and ESC-derived regulatory T cells
2020-04-17 12:30 ET
Sangamo Appoints D. Mark McClung as Executive Vice President and Chief Business Officer
2020-04-09 12:00 ET
Sangamo Announces Closing of Biogen Collaboration Agreement
2020-03-02 13:30 ET
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
2020-02-28 12:00 ET
Sangamo Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
2020-02-27 21:06 ET
Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimer’s, Parkinson’s, Neuromuscular, and Other Neurological Diseases
2020-02-27 21:06 ET
Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimer’s, Parkinson’s, Neuromuscular, and Other Neurological Diseases
2020-02-25 21:30 ET
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2019 Conference Call and Webcast
2020-02-12 13:00 ET
Sangamo Therapeutics Appoints John Markels to Its Board of Directors
2020-01-09 13:30 ET
Sangamo Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
2019-12-23 11:50 ET
Sangamo Announces Early Completion of Transfer to Pfizer of SB-525 Hemophilia A Gene Therapy IND and an Earned $25 Million Milestone Payment
2019-12-17 11:45 ET
Sangamo Highlights Advancements in Genomic Medicine Pipeline and Expanded R&D and Manufacturing Capabilities at R&D Day
2019-12-06 13:30 ET
Sangamo to Highlight Genomic Medicine Pipeline, Technology Platforms, and Manufacturing Capabilities in December 17 R&D Day
2019-11-26 13:30 ET
Sangamo Therapeutics Appoints James R. Meyers to Its Board of Directors
2019-11-08 13:30 ET
Sangamo Therapeutics Announces New Scientific Advisory Board
2019-11-06 21:01 ET
Sangamo Therapeutics Reports Third Quarter 2019 Financial Results
2019-11-01 12:01 ET
Sangamo Therapeutics Appoints Sung Lee as Executive Vice President and Chief Financial Officer
2019-10-30 20:15 ET
Sangamo Therapeutics Announces Third Quarter 2019 Conference Call and Webcast
2019-09-30 20:15 ET
Sangamo Therapeutics Appoints Bettina M. Cockroft, MD, MBA, as Senior Vice President and Chief Medical Officer
2019-09-30 12:30 ET
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
2019-07-31 20:15 ET
Sangamo Therapeutics Appoints Gary H. Loeb as Executive Vice President and General Counsel
2019-07-31 20:05 ET
Sangamo Therapeutics Announces Second Quarter 2019 Conference Call and Webcast
2019-07-08 13:31 ET
Thinking about buying stock in Apple, Aurora Cannabis, Oasmia Pharmaceutical, Sangamo Therapeutics, or Symantec?
2019-06-21 13:16 ET
Sangamo Announces Upcoming Presentation Of Investigational SB-525 Hemophilia A Gene Therapy Data At ISTH 2019
2019-05-10 12:30 ET
Sangamo Therapeutics Announces Participation In The Bank Of America Merrill Lynch 2019 Health Care Conference
2019-05-01 20:01 ET
Sangamo Therapeutics Announces First Quarter 2019 Conference Call And Webcast
2019-04-15 20:01 ET
Sangamo Therapeutics Announces Presentations At 2019 Annual Meeting Of The American Society Of Gene & Cell Therapy
2019-04-08 20:01 ET
Sangamo Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
2019-04-04 12:00 ET
Sangamo Therapeutics Announces Pricing of Public Offering of Common Stock
2019-04-03 20:01 ET
Sangamo Therapeutics Announces Proposed Public Offering of Common Stock
2019-04-02 11:00 ET
Sangamo and Pfizer Announce Phase 1/2 Interim Data For Investigational Hemophilia A Gene Therapy
2019-04-02 11:00 ET
Sangamo Provides Clinical Development Update Including Early Phase 1/2 Beta Thalassemia Gene-edited Cell Therapy Data
2019-04-01 20:43 ET
Sangamo Therapeutics To Host April 2, 2019 Conference Call To Provide Clinical Update
2019-03-29 11:00 ET
Sangamo Therapeutics Presents New Preclinical Data Demonstrating Significant Reduction In Tau Expression With Gene Regulation Technology

SEC forms

Show financial reports only

SEC form 8
2024-03-13 07:55 ET
Sangamo Therapeutics reported for 2023 q4
SEC form 8
2024-03-13 07:55 ET
Sangamo Therapeutics published news for 2023 q4
SEC form 10
2024-03-13 07:47 ET
Sangamo Therapeutics published news for 2023 q4
SEC form 10
2024-03-13 00:00 ET
Sangamo Therapeutics published news for 2023 q4
SEC form 10
2023-11-01 16:17 ET
Sangamo Therapeutics reported for 2023 q3
SEC form 8
2023-11-01 16:02 ET
Sangamo Therapeutics reported for 2023 q3
SEC form 10
2023-11-01 00:00 ET
Sangamo Therapeutics reported for 2023 q3
SEC form 10
2023-08-08 16:15 ET
Sangamo Therapeutics reported for 2023 q2
SEC form 6
2023-08-08 16:08 ET
Sangamo Therapeutics reported for 2023 q2
SEC form 8
2023-08-08 00:00 ET
Sangamo Therapeutics reported for 2023 q2
SEC form 10
2023-08-08 00:00 ET
Sangamo Therapeutics reported for 2023 q2
SEC form 10
2023-05-08 00:00 ET
Sangamo Therapeutics reported for 2023 q1
SEC form 8
2023-04-26 00:00 ET
Sangamo Therapeutics published news for 2023 q1
SEC form 6
2023-03-17 17:14 ET
Sangamo Therapeutics published news for 2022 q4
SEC form 6
2023-03-14 09:43 ET
Sangamo Therapeutics published news for 2022 q4
SEC form 6
2023-03-10 17:17 ET
Sangamo Therapeutics published news for 2022 q4
SEC form 6
2023-03-07 06:49 ET
Sangamo Therapeutics published news for 2022 q4
SEC form 6
2023-03-02 17:05 ET
Sangamo Therapeutics published news for 2022 q4
SEC form 10
2023-02-23 00:00 ET
Sangamo Therapeutics reported for 2022 q4
SEC form 10
2023-02-22 21:45 ET
Sangamo Therapeutics reported for 2022 q4
SEC form 6
2023-02-22 16:03 ET
Sangamo Therapeutics published news for 2022 q4
SEC form 8
2023-02-22 00:00 ET
Sangamo Therapeutics reported for 2022 q4
SEC form 6
2022-12-23 16:02 ET
Sangamo Therapeutics published news for 2022 q3
SEC form 6
2022-12-19 16:09 ET
Sangamo Therapeutics published news for 2022 q3
SEC form 6
2022-12-09 19:01 ET
Sangamo Therapeutics published news for 2022 q3
SEC form 10
2022-11-03 16:02 ET
Sangamo Therapeutics reported for 2022 q3
SEC form 6
2022-11-03 16:01 ET
Sangamo Therapeutics published news for 2022 q3
SEC form 10
2022-11-03 00:00 ET
Sangamo Therapeutics reported for 2022 q3
SEC form 8
2022-11-03 00:00 ET
Sangamo Therapeutics reported for 2022 q3
SEC form 6
2022-10-11 21:16 ET
Sangamo Therapeutics published news for 2022 q3
SEC form 6
2022-09-22 17:00 ET
Sangamo Therapeutics published news for 2022 q2
SEC form 6
2022-08-30 06:06 ET
Sangamo Therapeutics published news for 2022 q2
SEC form 6
2022-08-09 16:18 ET
Sangamo Therapeutics published news for 2022 q2
SEC form 10
2022-08-04 17:01 ET
Sangamo Therapeutics reported for 2022 q2
SEC form 6
2022-08-04 16:03 ET
Sangamo Therapeutics published news for 2022 q2
SEC form 8
2022-08-04 00:00 ET
Sangamo Therapeutics reported for 2022 q2
SEC form 10
2022-08-04 00:00 ET
Sangamo Therapeutics reported for 2022 q2
SEC form 6
2022-05-25 17:21 ET
Sangamo Therapeutics published news for 2022 q1
SEC form 10
2022-05-05 16:05 ET
Sangamo Therapeutics reported for 2022 q1
SEC form 6
2022-05-05 16:03 ET
Sangamo Therapeutics published news for 2022 q1
SEC form 8
2022-05-05 00:00 ET
Sangamo Therapeutics reported for 2022 q1
SEC form 10
2022-05-05 00:00 ET
Sangamo Therapeutics reported for 2022 q1
SEC form 6
2022-04-01 16:09 ET
Sangamo Therapeutics published news for 2022 q1
SEC form 6
2022-04-01 16:05 ET
Sangamo Therapeutics published news for 2022 q1
SEC form 6
2022-03-28 16:06 ET
Sangamo Therapeutics published news for 2021 q4
SEC form 10
2022-02-24 16:11 ET
Sangamo Therapeutics published news for 2021 q4
SEC form 6
2022-02-24 16:03 ET
Sangamo Therapeutics published news for 2021 q4
SEC form 8
2022-02-24 00:00 ET
Sangamo Therapeutics published news for 2021 q4
SEC form 10
2022-02-24 00:00 ET
Sangamo Therapeutics published news for 2021 q4
SEC form 6
2022-02-08 21:41 ET
Sangamo Therapeutics published news for 2021 q4
SEC form 6
2022-01-06 06:54 ET
Sangamo Therapeutics published news for 2021 q4
SEC form 6
2021-12-13 09:01 ET
Sangamo Therapeutics published news for 2021 q3
SEC form 6
2021-11-19 19:37 ET
Sangamo Therapeutics published news for 2021 q3
SEC form 10
2021-11-04 09:11 ET
Sangamo Therapeutics published news for 2021 q3
SEC form 6
2021-11-04 09:05 ET
Sangamo Therapeutics published news for 2021 q3
SEC form 10
2021-11-04 00:00 ET
Sangamo Therapeutics published news for 2021 q3
SEC form 8
2021-11-04 00:00 ET
Sangamo Therapeutics published news for 2021 q3
SEC form 6
2021-10-22 16:04 ET
Sangamo Therapeutics published news for 2021 q3
SEC form 10
2021-08-05 16:18 ET
Sangamo Therapeutics published news for 2021 q2
SEC form 6
2021-08-05 16:08 ET
Sangamo Therapeutics published news for 2021 q2
SEC form 10
2021-08-05 00:00 ET
Sangamo Therapeutics published news for 2021 q2
SEC form 8
2021-08-05 00:00 ET
Sangamo Therapeutics published news for 2021 q2
SEC form 6
2021-07-01 16:31 ET
Sangamo Therapeutics published news for 2021 q2
SEC form 6
2021-05-28 16:31 ET
Sangamo Therapeutics published news for 2021 q1
SEC form 6
2021-05-27 17:28 ET
Sangamo Therapeutics published news for 2021 q1
SEC form 10
2021-05-04 16:17 ET
Sangamo Therapeutics published news for 2021 q1
SEC form 6
2021-05-04 16:08 ET
Sangamo Therapeutics published news for 2021 q1
SEC form 8
2021-05-04 00:00 ET
Sangamo Therapeutics published news for 2021 q1
SEC form 10
2021-05-04 00:00 ET
Sangamo Therapeutics published news for 2021 q1
SEC form 6
2021-04-02 16:12 ET
Sangamo Therapeutics published news for 2021 q1
SEC form 6
2021-03-17 17:06 ET
Sangamo Therapeutics published news for 2020 q4
SEC form 10
2021-02-24 16:17 ET
Sangamo Therapeutics published news for 2020 q4
SEC form 6
2021-02-24 16:10 ET
Sangamo Therapeutics published news for 2020 q4
SEC form 6
2021-01-27 20:07 ET
Sangamo Therapeutics published news for 2020 q4
SEC form 6
2021-01-14 09:01 ET
Sangamo Therapeutics published news for 2020 q4
SEC form 6
2021-01-06 16:22 ET
Sangamo Therapeutics published news for 2020 q4
SEC form 6
2020-12-15 16:00 ET
Sangamo Therapeutics published news for 2020 q3
SEC form 6
2020-12-07 07:32 ET
Sangamo Therapeutics published news for 2020 q3
SEC form 10
2020-11-04 16:23 ET
Sangamo Therapeutics published news for 2020 q3
SEC form 6
2020-11-04 16:06 ET
Sangamo Therapeutics published news for 2020 q3